I agree that this site is using cookies. You can find further informations here.
X
Gritti, G
217  results:
Search for persons X
?
1

Exposure to obinutuzumab does not affect outcomes of SARS‐C..:

Pinto, A. ; Caltagirone, M. ; Battista, M....
British Journal of Haematology.  , 2024
Link: https://doi.org/10.1111/..
 
?
2

SAKK 38/19: ASSESSING A CTDNA AND PET‐ORIENTED THERAPY IN P..:

Stathis, A. ; Hitz, F. ; Schär, S....
Hematological Oncology.  41 (2023)  S2 - p. 165-166 , 2023
Link: https://doi.org/10.1002/..
 
?
3

GLOFITAMAB PLUS POLATUZUMAB VEDOTIN DEMONSTRATES DURABLE RE..:

Hutchings, M. ; Avigdor, A. ; Sureda, A....
Hematological Oncology.  41 (2023)  S2 - p. 138-140 , 2023
Link: https://doi.org/10.1002/..
 
?
4

COMBINING CD19‐4‐1BBL (RO7227166) WITH GLOFITAMAB IS SAFE A..:

Hutchings, M. ; Dickinson, M. ; Carlo‐Stella, C....
Hematological Oncology.  41 (2023)  S2 - p. 136-138 , 2023
Link: https://doi.org/10.1002/..
 
?
5

Duvelisib in patients with relapsed/refractory peripheral T..:

Mehta‐Shah, N. ; Jacobsen, E. D. ; Zinzani, P. L....
Hematological Oncology.  41 (2023)  S2 - p. 499-500 , 2023
Link: https://doi.org/10.1002/..
 
?
6

P1239: TISLELIZUMAB, A PD-1 INHIBITOR FOR RELAPSED/REFRACTO..:

Bachy, E. ; Savage, K. J. ; Huang, H....
HemaSphere.  6 (2022)  - p. 1124-1125 , 2022
Link: https://doi.org/10.1097/..
 
?
7

P1172: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIP..:

Zinzani, P. L. ; Zain, J. ; Mead, M....
HemaSphere.  6 (2022)  - p. 1058-1059 , 2022
Link: https://doi.org/10.1097/..
 
?
8

Skip pattern approach toward the early access of innovative..:

Apolone, G. ; Ardizzoni, A. ; Biondi, A....
ESMO Open.  6 (2021)  4 - p. 100227 , 2021
Link: https://doi.org/10.1016/..
 
?
9

POLATUZUMAB VEDOTIN + OBINUTUZUMAB + VENETOCLAX IN PATIENTS..:

Bannerji, R. ; Yuen, S. ; Phillips, T....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
10

NIVOLUMAB PLUS BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY ..:

Zinzani, P. L. ; Santoro, A. ; Gritti, G....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
11

A NON‐INTERVENTIONAL STUDY OF OBINUTUZUMAB IN PATIENTS WITH..:

., A ; . Zinzani, P. L ; . Arcaini, L...
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
12

DEVELOPMENT AND VALIDATION OF A PET RADIOMICS PROGNOSTIC MO..:

Ceriani, L ; Milan, L ; Cascione, L...
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
13

Chimeric antigen receptor T cells for gamma–delta T cell ma..:

Wawrzyniecka, P. A. ; Ibrahim, L. ; Gritti, G...
Leukemia.  36 (2021)  2 - p. 577-579 , 2021
Link: https://doi.org/10.1038/..
 
?
14

NIVOLUMAB COMBINED WITH BRENTUXIMAB VEDOTIN FOR RELAPSED/RE..:

Zinzani, P.L. ; Santoro, A. ; Gritti, G....
Hematological Oncology.  37 (2019)  S2 - p. 157-158 , 2019
Link: https://doi.org/10.1002/..
 
?
15

DURABILITY OF COMPLETE RESPONSE AFTER BLINATUMOMAB THERAPY ..:

Viardot, A. ; Hess, G. ; Bargou, R....
Hematological Oncology.  37 (2019)  S2 - p. 429-430 , 2019
Link: https://doi.org/10.1002/..
 
1-15